Trump Administration Cancels $6.7 Million Grant for Life-Saving Infant Heart Device Research

In a controversial move, the Trump administration has halted federal funding for a critical medical research project aimed at developing a life-saving heart device for infants with congenital heart defects. The Department of Defense rescinded a $6.7 million grant awarded to Dr. James Antaki, a biomedical engineering professor at Cornell University, for the development of the PediaFlow device.

PediaFlow, a miniature heart pump approximately the size of an AA battery, is designed to assist blood circulation in infants suffering from severe heart conditions. This device potentially improves survival rates until they can undergo surgery or receive a heart transplant. PediaFlow has been in development since 2003 and represents decades of research and innovation.

The grant, initially awarded on March 30, intended to support the scaling up of production and testing of PediaFlow. However, on April 8, 2025 the Department of Defense issued a stop-work order. This effectively terminated the funding without providing a clear explanation. This abrupt cancellation has jeopardized the future of the project. Dr. Antaki now expresses concerns about potential staff reductions and the need for PhD students to redirect their research efforts.

The decision has drawn criticism from the medical community. Dr. Evan Zahn, a pediatric interventional cardiologist at Cedars-Sinai Medical Center, emphasized the importance of such technology. He stated that losing funding for devices specifically designed for infants is a significant setback for pediatric research.

Cuts across the board

This funding cut is part of a broader initiative by the Trump administration to reduce federal spending on scientific research. Critics argue that such actions undermine critical medical advancements and public health initiatives. The cancellation of the PediaFlow grant has sparked a debate about the role of government in supporting life-saving medical research, especially for vulnerable populations like infants with congenital heart defects.

As the medical community grapples with the implications of this decision, the future of PediaFlow remains uncertain. Dr. Antaki and his team continue to seek alternative funding sources to ensure the continuation of their vital work in developing innovative solutions for pediatric heart care.